In breast cancer, vascular endothelial growth factor (VEGF) and hypoxia inducible factor (HIF)-1 are elevated in hypoxic environments, which attenuates the effects of CDK4/6 inhibitors [22, 24, 25]. This evidence concerns the gene VEGFA and breast cancer.